43 studies found for:    ovarian small cell carcinoma | Open Studies | Exclude Unknown | Interventional Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine
Interventions: Drug: Topotecan;   Drug: VX-970
2 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Breast Cancer;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Bladder Cancer;   Cervical Cancer;   Endometrial Cancer
Intervention: Drug: IMMU-132
3 Recruiting Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Conditions: Small Cell Lung Carcinoma;   Non Small Cell Lung Carcinoma;   Irinotecan Sensitive Cancers
Interventions: Drug: Carfilzomib;   Drug: Irinotecan
4 Recruiting Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Conditions: Ovarian Cancer;   Adverse Effects
Intervention: Drug: Sunitinib
5 Recruiting CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
6 Recruiting Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Solid Tumors
Interventions: Drug: STM 434;   Drug: Liposomal doxorubicin
7 Recruiting HYPAZ: Hypertension Induced by Pazopanib
Conditions: Renal Cell Carcinoma;   Soft Tissue Sarcoma;   Glioblastoma;   Ovarian Cancer;   Cervical Cancer;   Breast Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Pancreatic Cancer;   Melanoma;   Gastrointestinal Cancer
Intervention: Drug: Pazopanib
8 Recruiting Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Conditions: Breast Cancer;   Ovarian Cancer;   Gynecological Cancer;   Head and Neck Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Non-squamous Cell Lung Cancer
Intervention: Drug: PM01183 + paclitaxel +/- bevacizumab
9 Recruiting Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions: Genetic: DNA analysis;   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8;   Radiation: 131I-3F8
10 Recruiting Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumors;   Ovarian Cancer;   Small Cell Lung Cancer
Interventions: Drug: Alisertib;   Drug: Paclitaxel
11 Recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Condition: Tumor or Lymphoma
Interventions: Drug: JNJ-42756493: Part 1;   Drug: JNJ-42756493: Part 2;   Drug: JNJ-42756493: Part 3;   Drug: JNJ-42756493: Part 4
12 Recruiting ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Condition: Solid Tumors
Interventions: Drug: ME-344;   Drug: Topotecan
13 Recruiting Study of BMS-986158 in Subjects With Select Advanced Solid Tumors
Condition: Multiple Indications Cancer
Interventions: Drug: BMS-986158;   Drug: Paclitaxel
14 Recruiting Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Tumor;   Fallopian Tube Mucinous Neoplasm;   Fallopian Tube Serous Neoplasm;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
15 Recruiting MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Conditions: Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Clear Cell Tumor;   Malignant Ovarian Endometrioid Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Malignant Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Gemcitabine Hydrochloride;   Drug: Topotecan Hydrochloride;   Drug: Paclitaxel;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
16 Not yet recruiting Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
17 Recruiting Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Conditions: HIV Infection;   Recurrent Anal Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Anal Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: carboplatin;   Drug: paclitaxel
18 Recruiting Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
Conditions: Adult Solid Neoplasm;   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Recurrent Colorectal Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Ovarian Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Ziv-Aflibercept
19 Recruiting A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers
Conditions: Melanoma;   Carcinoma, Non-Small-Cell Lung;   Colorectal Neoplasms;   Carcinoma, Squamous Cell of Head and Neck;   Ovarian Neoplasms;   B Cell NHL or HL Including DLBCL
Intervention: Drug: Nivolumab + INCB24360
20 Recruiting A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Gemcitabine;   Drug: pazopanib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years